Abstract:The early and accurate identification of predictive biomarkers for antiviral treatment efficacy remains a significant clinical challenge, particularly in the management of chronic hepatitis B (CHB). This study aimed to assess whether the plasma metabolome could reliably predict the success of antiviral therapy in CHB patients. We conducted a retrospective analysis on 56 treatment-naive CHB patients at the First Affiliated Hospital of Zhejiang University from December 2013 to March 2016. Patients who underwent a 48-week treatment regimen of entecavir (ETV) and interferon-alpha (IFN-α) were randomly assigned to either a discovery cohort (n=29) or a validation cohort (n=27). Based on the outcome of the treatment, patients were classified as HBeAg seroconversion group (High responders, Hrp) or the non-remission group (Low responder, Lrp). Our methodology involved an untargeted analysis of the amine/phenol and carboxylic acid submetabolomes in the CHB patients under treatment, utilizing chemical isotope labeling (CIL) techniques with liquid chromatography-mass spectrometry (LC-MS). Several metabolites were identified as having significant diagnostic potential for distinguishing Hrp from Lrp, with areas under the receiver operating characteristic curve (AUC) exceeding those typical clinical indicators. Notably, four metabolites, namely 2-methyl-3-ketovaleric acid, 2-ketohexanoic acid, 6-oxo-1,4,5,6-tetrahydronicotinic acid, and α-ketoisovaleric acid, demonstrated exceptionally high sensitivity and specificity in both cohorts, nearing 100%. In contrast, the clinical indicators, including HBcAb, log(HBsAg), and HBeAb, demonstrated lower and inconsistent sensitivity and specificity between the discovery and validation cohorts. Using HBcAb as a marker, the sensitivity was 87.5% with 76.9% specificity in the discovery cohort; however, the sensitivity dropped to 46.7% with 91.7% specificity in the validation cohort. Using log(HBsAg), the sensitivity was 84.6% with 69.2% specificity in the discovery cohort, compared to 85.7% sensitivity and 83.3% specificity in the validation cohort. For HBeAb, the separation of Hrp and Lrp had a sensitivity of 87.5% with 69.2% specificity in the discovery cohort, while the validation cohort showed 86.7% sensitivity and 91.7% specificity.

Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy

HBcrAgandpgRNAand the therapeutic effect inHBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNAis a powerful predictor of response.

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles

Serum Microrna‐29 Levels Correlate with Disease Progression in Patients with Chronic Hepatitis B Virus Infection

Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients

The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.

Plasma Microrna Profile As a Predictor of Early Virological Response to Interferon Treatment in Chronic Hepatitis B Patients

Serum MicroRNA Levels As a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis

Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients

Circulating Human Cytomegalovirus-Encoded Hcmv-Mir-Us4-1 As An Indicator For Predicting The Efficacy Of Ifn Alpha Treatment In Chronic Hepatitis B Patients

MicroRNAs may solve the mystery of chronic hepatitis B virus infection.

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

MicroRNA Profile in HBV-induced Infection and Hepatocellular Carcinoma.

The Relationship Between Serum Exosome HBV-miR-3 and Current Virological Markers and Its Dynamics in Chronic Hepatitis B Patients on Antiviral Treatment

Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.

Baseline Serum Exosome-Derived Mirnas Predict HBeAg Seroconversion in Chronic Hepatitis B Patients Treated with Peginterferon

Plasma metabolome analysis for predicting antiviral treatment efficacy in chronic hepatitis B: diagnostic biomarkers and therapeutic insights

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir